Showing results (81-90 of 107) with videos related to
Sort By:
Pageof 11
The Lancet. Oncology|September 3, 2019
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trialMansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J Birrer, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 24, 2024
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancerAlejandro Perez-Fidalgo, Barbara Schmalfeldt, Angela George, et al.Gynecologic Oncology|December 10, 2024
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trialMansoor R Mirza, Line Bjørge, Frederik Marmé, et al.Translational Oncology|March 20, 2026
Exploring survival-associated transcriptomic subtypes in ovarian cancer using RNAseq from FFPE tissues in a clinical trial cohortMaj K Kjeldsen, Frederik Otzen Bagger, Henrik Roed, et al.Oncotarget|October 6, 2017
Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancersAnna Berg, Ankush Gulati, Sigmund Ytre-Hauge, et al.Journal for Immunotherapy of Cancer|April 11, 2024
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16Nicholas P Casey, Katrin Kleinmanns, Christopher Forcados, et al.Ebiomedicine|February 3, 2026
A 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy responseChristiane Helgestad Gjerde, Katrin Kleinmanns, Anika Langer, et al.International Journal of Cancer|December 19, 2022
The WID-EC test for the detection and risk prediction of endometrial cancerJames E Barrett, Allison Jones, Iona Evans, et al.International Journal of Cancer|August 6, 2019
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancerIsabelle Ray-Coquard, David Cibula, Mansoor R Mirza, et al.Cell Reports. Medicine|September 9, 2025
Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumorsRafaela Abrantes, Christopher Forcados, David J Warren, et al.Pageof 11